That classification makes it hard to pursue large-level trials that could demonstrate cannabidiol’s safety and efficiency in epilepsy, Friedman said. Right now, the evidence for the utility of cannabinoids, and cannabidiol particularly, for the treatment of severe epilepsy is intriguing, but the definitive proof is not there yet, Friedman said. Epilepsy Foundation President and CEO Phil Gattone said the review highlights just how current federal laws have limited our knowledge of marijuana’s potential effectiveness seeing that an anti-seizure medication.The study target for the time from qualifying imaging to groin puncture was within 70 minutes. Outcome Measures The primary study-outcome measure was disability at 3 months, as assessed by way of the modified Rankin scale, a worldwide way of measuring disability on a seven-level scale, with scores ranging from 0 to 6 . or 3 21; and effective reperfusion at 27 hours in both study groups, which was thought as reperfusion of 90 percent or more of the original perfusion-lesion quantity, as assessed through perfusion imaging at 27 hours after randomization.